Small Lymphocytic Lymphoma

• CLINICAL_TRIALS trial_result · 2023-09-21
  Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]

  Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…

• CLINICAL_TRIALS trial_result · 2023-08-14
  Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

  Phase 3 trial comparing ibrutinib plus rituximab versus FCR in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma; status …

• CLINICAL_TRIALS trial_result · 2023-08-14
  Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

  This Phase 3 trial compares ibrutinib plus rituximab against fludarabine phosphate, cyclophosphamide, and rituximab in previously untreated …

• CLINICAL_TRIALS trial_result · 2023-08-08
  Clinical Trial Update: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  Clinical trial updating on the use of entospletinib with obinutuzumab in relapsed CLL/SLL or NHL; Phase 1/2 study status completed with resu…

• CLINICAL_TRIALS trial_result · 2023-07-27
  Clinical Trial Update: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 3]

  Phase 3 study comparing zanubrutinib to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma has com…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2023-07-24
  Clinical Trial Update: Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma [Phase 2]

  Phase 2 trial of umbralisib plus ublituximab in treatment-naïve follicular lymphoma was terminated; results posted in 2023.

• CLINICAL_TRIALS trial_result · 2023-07-13
  Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]

  Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and re…

• CLINICAL_TRIALS trial_result · 2023-06-27
  Clinical Trial Update: Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL [Phase 2]

  Phase 2 trial evaluating bendamustine/rituximab induction followed by maintenance rituximab and lenalidomide in previously untreated CLL/SLL…

• CLINICAL_TRIALS trial_result · 2023-06-09
  Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]

  Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …

• CLINICAL_TRIALS trial_result · 2023-06-05
  Clinical Trial Update: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL [Phase 3]

  A Phase 3 trial comparing ICP-022 to chlorambucil plus rituximab in untreated CLL/SLL is underway, with status currently unknown.

• CLINICAL_TRIALS trial_result · 2023-04-19
  Clinical Trial Update: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

  A Phase 2 trial evaluating the combination of ibrutinib, fludarabine, and pembrolizumab in high-risk or relapsed/refractory chronic lymphocy…

• CLINICAL_TRIALS trial_result · 2023-03-21
  Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]

  Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…

• CLINICAL_TRIALS trial_result · 2023-02-21
  Clinical Trial Update: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 [Phase 3]

  Phase 3 extension study in chronic lymphocytic leukemia/small lymphocytic lymphoma evaluating duvelisib with ofatumumab has completed enroll…

• CLINICAL_TRIALS trial_result · 2023-02-09
  Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]

  Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…

• CLINICAL_TRIALS trial_result · 2023-01-31
  Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]

  Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic…

• CLINICAL_TRIALS trial_result · 2022-11-21
  Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.

• CLINICAL_TRIALS trial_result · 2022-11-03
  Clinical Trial Update: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy [Phase 3]

  A Phase 3 study in previously untreated chronic lymphocytic leukemia (excluding 17p deletion) evaluating debulking regimens before starting …

• CLINICAL_TRIALS trial_result · 2022-11-03
  Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]

  Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…

• CLINICAL_TRIALS trial_result · 2022-09-28
  Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

  Phase 2 clinical trial of lenalidomide and obinutuzumab in patients with recurrent or refractory chronic lymphocytic leukemia or small lymph…

• CLINICAL_TRIALS trial_result · 2022-09-19
  Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]

  Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…

• CLINICAL_TRIALS trial_result · 2022-09-10
  Clinical Trial Update: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia [Phase 1, Phase 2]

  ACP-196 (acalabrutinib), a BTK inhibitor, is being studied in Phase 1/2 trials for chronic lymphocytic leukemia, Richter's syndrome, small l…

• CLINICAL_TRIALS trial_result · 2022-07-21
  Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]

  Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…

• CLINICAL_TRIALS trial_result · 2022-07-20
  Clinical Trial Update: Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL [Phase 2]

  A Phase 2 trial evaluating the combination of lenalidomide and azacitidine for relapsed/refractory chronic lymphocytic leukemia and small ly…

• CLINICAL_TRIALS trial_result · 2022-07-06
  Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With CLL/ SLL [Phase 1, Phase 2]

  Clinical trial update on ICP-022 for chronic lymphocytic leukemia and small lymphocytic lymphoma (early-phase study).

• CLINICAL_TRIALS trial_result · 2022-05-25
  Clinical Trial Update: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

  Phase 1/2 trial evaluating laboratory-treated T cells in relapsed or refractory B-cell malignancies and acute lymphoblastic leukemia.